CLOs on the Move

PROSPECT 33

www.prospect33.com

 
PROSPECT 33 is a Warrenton, VA-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Command Post Technologies

We are Command Post Technologies, Inc. (CPT). Headquartered in Suffolk, VA with a presence in El Paso, TX and Washington D.C., CPT is a service disabled veteran owned small business (SDVOSB) founded in 2008. We support Joint and Services Test and Evalu...

Eichleay

Eichleay (IKE lee) provides a comprehensive range of integrated engineering, architectural, project and construction management services. We are in the business of project delivery and our professional technical services span the entire life of a project. With over a nearly 140 year history, the Eichleay family of companies has developed expertise in a wide range of fields with an emphasis on industrial process, manufacturing, life science, and high technology facilities. Our experienced, dedicated team develops custom-tailored solutions that meet your complex needs, helping you save time and money and maximize the efficiency and effectiveness of your operations. With offices in the San Francisco Bay and Los Angeles Areas, we will work anywhere our clients do.

Repeatsys

Repeatsys is a American Fork, UT-based company in the Business Services sector.

CN Bio

We generate human-specific efficacy and safety data with pioneering PhysioMimix™ single- and multi-organ-on-a-chip solutions. Our advantage comes from having had almost unparalleled resources to invest in the development of leading edge organ-chips thanks to more than $32 Million in grants and contracts from DARPA, NIH, EU FP7, Innovate UK and NC3Rs. These programs have led to the development of a 7-organ human body-on-a-chip model (DARPA), a liver-on-a-chip model of cancer metastasis (NIH), a full viral lifecycle organ-chip model of hepatitis B and a liver-on-a-chip model of non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). CN Bio is at the forefront of translating these promising technologies from leading academic laboratories into the hands of pharmaceutical researchers for the development of new medicines to treat and cure disease and to the wider academic community seeking to understand biology and disease pathology using technologies which more closely represent the human response.